Phase II and III Covaxin trials for today’s pediatric use and vaccines can be available for this age group in September or as soon as possible, said Dr.
Priya Abraham, Director of the ICMR-National Institute of Virology Pune.
Quotes from interviews: How many covaxin trials in children advanced and when the vaccine can be expected? At present, Phase II and III Covaxin trials are underway for children between 2-18 years.
Hopefully, the results will be available soon.
They will be presented to the regulator.
So, in September or after that, we might have a Covid-19 vaccine for children.
This is separate, the Zydus Cadila vaccine trial also takes place for children.
Apart from this, what other vaccines exist in the pipe? The Zydus Cadila vaccine will be the first DNA vaccine available for use.
In addition, there is a M-RNA Gennova Biopharmaceuticals Ltd vaccine, biological vaccine-e, Indian novovax serum institute and, the only interesting intranasal vaccine developed by Bharat Biotech, which does not require Jab and can be sent through nostrils.
Are there vaccines available effectively on Delta Plus variants? First, the Delta-Plus variant tends to spread than Delta, which is present in more than 130 countries.
In NIV, we have studied antibodies produced in people who were vaccinated and examined them against this variant.
We found that the efficacy of antibodies to deltas reduced two to three times.
However, a protective vaccine against the variant.
Do we need a booster dose? Are there research conducted? Studies have occurred abroad.
At least seven different vaccines have been tried for a booster dose.
Now, who stops it until more countries pursue vaccinations.
What are the mixing and matching vaccines studied? There are situations where two different vaccines are given in two doses.
We have tested the sample in NIV and found that patients were safe.
There are no side effects recorded.